The Dermatology Digest

22/01/2024

BREAKING NEWS: Arcutis Biotherapeutics, Inc.’s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis.

Arcutis Biotherapeutics, Inc.’s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. The U.S. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment

21/01/2024

Evommune, Inc. is initiating its Phase 1 first-in-human study, evaluating EVO756 in chronic spontaneous urticaria (CSU).

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch.

Evommune, Inc. is initiating its Phase 1 first-in-human study, evaluating EVO756 in chronic spontaneous urticaria (CSU). By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to

20/01/2024

The alopecia areata treatment landscape continues to make important advancements. In part 4 of this educational series, Dr. George Han discusses the pathogenesis of areata, potential clinical targets, and new and emerging systemic therapies for .

The alopecia areata treatment landscape continues to make important advancements. In part 4 of this educational series, Dr. George Han discusses the pathogenesis of alopecia areata, potential clinical targets, and

20/01/2024

Programmed cell death 1 (PD-1) inhibitors have been approved for treating various types of cancer, but PD-1 functions can vary between different cell and cancer types, either promoting or suppressing disease progression.

Programmed cell death 1 (PD-1) inhibitors have been approved for treating various types of cancer, but PD-1 functions can vary between different cell and cancer types, either promoting or suppressing

19/01/2024

One dose of significantly improves both frown lines and crow’s feet, when treated alone or simultaneously, and the results last for six months, according to research presented at the International Conference in Berlin.

One dose of RelabotulinumtoxinA significantly improves both frown lines and crow’s feet, when treated alone or simultaneously, and the results last for six months, according to research presented at the

19/01/2024

Just one treatment with STRATA’s TheraClear X helps clear cystic and papular acne, according to a poster slated to be presented at the Maui Derm 2024 Meeting to be held at the Grand Wailea in Maui, Hawaii from January 22-26, 2024.

Just one treatment with STRATA’s TheraClearX helps clear cystic and papular acne, according to a poster slated to be presented at the Maui Derm 2024 Meeting to be held at the Grand

17/01/2024

Chronic prurigo (CPG), including prurigo nodularis, is difficult to treat and dramatically affects quality of life.

So, how can dermatologists best assess whether a treatment working or not?

Chronic prurigo (CPG), including prurigo nodularis, is difficult to treat and dramatically affects quality of life.  So, how can dermatologists best assess whether a treatment working or not? Enter the

17/01/2024

Sofwave's revolutionary technology, already proven effective for facial lines and wrinkles, is now FDA cleared to improve skin laxity on the upper arms 🙌​

Chicago dermatologist Dr. Quenby Erickson mentions to The Dermatology Digest that, “It is not surprising that 93% of treated arms showed significant improvement in skin laxity rated by blinded reviewers. I have been using this technology for two years in my office, and patients are very happy!”​

Our non-invasive procedure is also cleared for lifting the brow, the neck area, reducing the appearance of cellulite*, and treating acne scars. ​

Trust in the power of Sofwave™ 🌊​

Erickson Cosmetic Dermatology & Lifestyle Medicine

*short-term​

16/01/2024

When it comes to acne scarring, an ounce of prevention is truly worth a pound of cure, finds new research in the Journal of Integrative Dermatology. Scarring is a known sequela

16/01/2024

Led by George Martin, MD, a dermatologist in Kihei, Maui Derm is considered a top-tier event in !

Hundreds of leading , residents, and industry insiders are heading to the island for an exciting meeting packed with practice-changing lectures, panel discussions, workshops, and late-breaking research on a wide array of medical, cosmetic, and practice management topics – with a lot of socializing mixed in.

This year’s agenda promises to keep pace with the dynamic activity and innovation happening within dermatology today, and attendees will be able to take what they learned from the podium and apply it to their practice immediately following the conference.

It’s almost Maui Derm time. Led by George Martin, MD, a dermatologist in Kihei, Maui Derm is considered a top-tier event in dermatology. Hundreds of leading dermatologists, residents, and industry

15/01/2024

New research suggests that skin microbiome diversity may be associated with skin aging.

For the study, researchers at the Center for Microbiome Innovation at UC San Diego analyzed data collected during 13 studies from L'Oréal, consisting of 16S rRNA amplicon sequence data and corresponding skin clinical data for more than 650 females aged 18 to 70.

New research suggests that skin microbiome diversity may be associated with skin aging. For the study, researchers at the Center for Microbiome Innovation (CMI) at the University of California San Diego

14/01/2024

Researchers from the University of Pennsylvania have discovered key insights into the molecular basis of skin color variations among African populations.

Their findings, published in Nature Genetics, broaden the understanding of human evolution and the genetics underpinning contemporary human skin color diversity.

Researchers from the University of Pennsylvania have discovered key insights into the molecular basis of skin color variations among African populations.  Their findings, published in Nature Genetics, broaden the understanding of

14/01/2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 times more likely to achieve Investigator’s Global Assessment (IGA) success with roflumilast foam (Zoryve, Arcutis), 0.3%, compared to an identical vehicle (78.8% Zoryve foam; 48.3% vehicle), according to a new subgroup analysis from STRATUM study.

People with seborrheic dermatitis who don’t use topical steroids are 3.5 times more likely to achieve Investigator’s Global Assessment (IGA) success with roflumilast foam (Zoryve, Arcutis), 0.3%, compared to an identical vehicle (78.8% Zoryve foam; 48.3%